Abstract

A "cytokine storm" is characterized by an increase in the release of many cytokines that cause lung tissue fibrosis and long-term damage. This disorder is distinguished by a rise in the total quantity of cytokines that are discharged into the bloodstream. It is not quite obvious if these changes occurred as a consequence of the immunomodulation that the medication provided or of the disease process itself. In addition, additional study is necessary to shed light on the possible connection that exists between these inflammatory markers and the development and severity of COVID-19. The current analysis was to report changes in the inflammatory markers in symptomatic COVID-19 patients and to link such changes with severity and prognosis

Description